{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:04:02Z","timestamp":1771956242832,"version":"3.50.1"},"reference-count":54,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,29]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sugemalimab plus chemotherapy significantly prolonged progression-free survival and overall survival in patients with advanced oesophageal squamous-cell carcinoma (ESCC). However, considering the high cost of sugemalimab, we evaluated the cost-effectiveness of sugemalimab plus chemotherapy in the first-line treatment for advanced ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A partitioned survival model with a 3-week cycle length and the lifetime time horizon was constructed to assess the cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced ESCC. The key survival data, drug costs, and utility values were obtained from the GEMSTONE-304 trial, YAOZHI database and the published literature. Total costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were measured. One-way and probabilistic sensitivity analyses were performed to evaluate the uncertainty and model stability. In addition, subgroup and scenario analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The Chinese healthcare system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A hypothetical Chinese cohort of patients with unresectable, locally advanced, recurrent or metastatic ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Sugemalimab plus chemotherapy versus chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measure<\/jats:title>\n                    <jats:p>Costs, QALYs, ICERs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the placebo plus chemotherapy, the sugemalimab plus chemotherapy provided an additional 0.36 QALYs, with an incremental cost of $44\u2009376.88. The result of ICER was $119\u2009400.69\/QALY, which was significantly higher than the willingness-to-pay (WTP) threshold of three times per capita gross domestic product ($38\u2009024.68\/QALY) in 2023. Sensitivity analysis revealed that the cost of sugemalimab, the discount rate and the utility values were the most influential parameters on the base-case analysis results. Subgroup analyses showed that programmed cell death - ligand 1 subgroup ICERs exhibited dose-dependent efficacy: the ICERs for sugemalimab plus chemotherapy versus placebo plus chemotherapy were $138\u2009739.23\/QALY and $108\u2009051.81\/QALY in advanced ESCC patients with 1 \u2264 combined positive score (CPS) &lt;10\u2009and CPS \u226510. Scenario analysis indicated that even with patient assistance programme, the total cost of the sugemalimab plus chemotherapy group ($23\u2009474.25) would be $15\u2009030.18 higher than that of the placebo plus chemotherapy group ($8444.07), which had an ICER of $40\u2009440.28\/QALY. When the price of sugemalimab decreased by 50% and 85%, the probabilities of sugemalimab plus chemotherapy being cost-effective were 0% and 100%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From a Chinese healthcare system perspective, sugemalimab plus chemotherapy as first-line treatment for advanced ESCC might not be a cost-effective treatment option at the WTP threshold of $38\u2009024.68\/QALY.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098021","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:10:31Z","timestamp":1771953031000},"page":"e098021","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China"],"prefix":"10.1136","volume":"16","author":[{"given":"Chunyan","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxiong","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medical Informatics and Engineering, Xuzhou Medical University, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-9140","authenticated-orcid":false,"given":"Ruigang","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026022409101006000_16.2.e098021.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600"},{"key":"2026022409101006000_16.2.e098021.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2026022409101006000_16.2.e098021.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy498"},{"key":"2026022409101006000_16.2.e098021.4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.34232","article-title":"The survival of esophageal cancer by subtype in China with comparison to the United States","volume":"152","author":"An","year":"2023","journal-title":"Int J Cancer"},{"key":"2026022409101006000_16.2.e098021.5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50)","volume":"20","author":"Kato","year":"2023","journal-title":"Esophagus"},{"key":"2026022409101006000_16.2.e098021.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100380","article-title":"Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score","volume":"7","author":"Leone","year":"2022","journal-title":"ESMO Open"},{"key":"2026022409101006000_16.2.e098021.7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3748\/wjg.v30.i19.2496","article-title":"Immunotherapy for esophageal cancer: Where are we now and where can we go","volume":"30","author":"Shoji","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2026022409101006000_16.2.e098021.8","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.annonc.2023.04.019","article-title":"O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"2026022409101006000_16.2.e098021.9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1396761","article-title":"Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis","volume":"15","author":"Cai","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"2026022409101006000_16.2.e098021.11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","article-title":"First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"2026022409101006000_16.2.e098021.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8"},{"key":"2026022409101006000_16.2.e098021.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70549-7"},{"key":"2026022409101006000_16.2.e098021.14","doi-asserted-by":"crossref","first-page":"1259574","DOI":"10.3389\/fonc.2023.1259574","article-title":"Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Oncol"},{"key":"2026022409101006000_16.2.e098021.15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14737167.2021.1893167","article-title":"Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments","volume":"21","author":"Rui","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026022409101006000_16.2.e098021.16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","article-title":"Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes","volume":"38","author":"Smare","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2026022409101006000_16.2.e098021.17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"2026022409101006000_16.2.e098021.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2020.07.580"},{"key":"2026022409101006000_16.2.e098021.19","unstructured":"National Bureau of statistics . Statistical bulletin of the People\u2019s Republic of China on national economic and social development. 2024. Available: https:\/\/www.stats.gov.cn\/sj\/zxfb\/202402\/t20240228_1947915.html"},{"key":"2026022409101006000_16.2.e098021.20","unstructured":"Liu G . China Guideline For Pharmacoeconomic Evaluations. Beijing: China Market Publishing House, 2020:27\u201346."},{"key":"2026022409101006000_16.2.e098021.21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026022409101006000_16.2.e098021.22","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"2026022409101006000_16.2.e098021.23","unstructured":"Yao zhi.com. 2023. Available: https:\/\/data.yaozh.com"},{"key":"2026022409101006000_16.2.e098021.24","doi-asserted-by":"crossref","first-page":"790373","DOI":"10.3389\/fonc.2021.790373","article-title":"Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"2026022409101006000_16.2.e098021.25","doi-asserted-by":"crossref","first-page":"1172242","DOI":"10.3389\/fimmu.2023.1172242","article-title":"Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026022409101006000_16.2.e098021.26","doi-asserted-by":"crossref","unstructured":"Zhou C , Wei J , Xu K , et al . . RMHP 2023;Volume 16:2447\u201358. 10.2147\/RMHP.S436750","DOI":"10.2147\/RMHP.S436750"},{"key":"2026022409101006000_16.2.e098021.27","doi-asserted-by":"crossref","first-page":"1092385","DOI":"10.3389\/fimmu.2023.1092385","article-title":"Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026022409101006000_16.2.e098021.28","doi-asserted-by":"crossref","first-page":"1055727","DOI":"10.3389\/fphar.2023.1055727","article-title":"Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"2026022409101006000_16.2.e098021.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4904"},{"key":"2026022409101006000_16.2.e098021.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1203980"},{"key":"2026022409101006000_16.2.e098021.32","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026022409101006000_16.2.e098021.33","first-page":"80","article-title":"Financial toxicity, Part I: a new name for a growing problem","volume":"27","author":"Zafar","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"2026022409101006000_16.2.e098021.34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.lungcan.2022.11.008","article-title":"Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC","volume":"174","author":"Chen","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"2026022409101006000_16.2.e098021.35","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1007\/s12325-023-02594-y","article-title":"The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China","volume":"40","author":"Cheng","year":"2023","journal-title":"Adv Ther"},{"key":"2026022409101006000_16.2.e098021.36","doi-asserted-by":"crossref","first-page":"1015702","DOI":"10.3389\/fpubh.2022.1015702","article-title":"Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"},{"key":"2026022409101006000_16.2.e098021.37","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1054405","article-title":"Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis","volume":"11","author":"Liang","year":"2023","journal-title":"Front Public Health"},{"key":"2026022409101006000_16.2.e098021.38","doi-asserted-by":"crossref","first-page":"1081750","DOI":"10.3389\/fonc.2022.1081750","article-title":"Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026022409101006000_16.2.e098021.39","doi-asserted-by":"crossref","first-page":"996914","DOI":"10.3389\/fphar.2022.996914","article-title":"Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.40","doi-asserted-by":"crossref","first-page":"881787","DOI":"10.3389\/fphar.2022.881787","article-title":"Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.41","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.893387","article-title":"Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Public Health"},{"key":"2026022409101006000_16.2.e098021.42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953671","article-title":"Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma","volume":"12","author":"Shao","year":"2022","journal-title":"Front Oncol"},{"key":"2026022409101006000_16.2.e098021.43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s12325-022-02402-z","article-title":"Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma","volume":"40","author":"Fang","year":"2023","journal-title":"Adv Ther"},{"key":"2026022409101006000_16.2.e098021.44","unstructured":"Central People\u2019s Government of the People\u2019s Republic of China . Catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance 2020. 2020. Available: http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-12\/28\/content_5574062.htm"},{"key":"2026022409101006000_16.2.e098021.45","doi-asserted-by":"crossref","first-page":"899966","DOI":"10.3389\/fonc.2022.899966","article-title":"Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"2026022409101006000_16.2.e098021.46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.967182","article-title":"First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China","volume":"13","author":"Shen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"2026022409101006000_16.2.e098021.48","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36"},{"key":"2026022409101006000_16.2.e098021.49","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221122733","article-title":"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis","volume":"14","author":"Cao","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026022409101006000_16.2.e098021.50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934275","article-title":"Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022409101006000_16.2.e098021.51","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s12325-022-02101-9","article-title":"Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis","volume":"39","author":"Zhu","year":"2022","journal-title":"Adv Ther"},{"key":"2026022409101006000_16.2.e098021.52","doi-asserted-by":"crossref","unstructured":"Adunlin G , Ferreri SP , Dong J , et al . Immuno-Oncology Medicines: Policy Implications and Economic Considerations. Innov Pharm 2019;10. doi:10.24926\/iip.v10i3.1799","DOI":"10.24926\/iip.v10i3.1799"},{"key":"2026022409101006000_16.2.e098021.53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11530650-000000000-00000","article-title":"Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US","volume":"28","author":"Bridges","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"2026022409101006000_16.2.e098021.54","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from nononcology drugs?","volume":"20","author":"Bae","year":"2014","journal-title":"J Manag Care Spec Pharm"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:10:40Z","timestamp":1771953040000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2024-098021"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098021","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}